The Latest Cardiac and Vascular News
Proxy allows for seamless data transmission and improved AI-based plaque analysis NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced a new workflow solution to its portfolio, Proxy. Cleerly Proxy is a software that allows Cleerly to seamlessly transmit data to care providers by […]
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022. The agreement allows […]
A short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that a preliminary […]
Verve Researchers Awarded Paul Dudley White International Scholar Award from the American Heart Association for Highest Ranked Abstract Submitted from the United States to Scientific Sessions 2022 BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease […]
Firibastat efficacy non-significant versus placebo The REFRESH study and the development of firibastat in cardiology have been stopped Cash of 11 million euros allotted to the development of new innovative treatments, after discontinuation of the REFRESH study PARIS, Oct. 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical […]
Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038 NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and […]
Analysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces a new program to address healthcare disparities in underserved communities, as new data provides an example of how better access to Impella heart pumps can improve health equity for non-Caucasian […]
alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months post-implantation: o 100% median per-patient reduction in therapeutic paracentesis (TP) post- vs preimplantation (p<0.001) o 77% of patients with at least 50% reduction in number of TP post- vs pre-implantation (p<0.001) alfapump primary safety endpoint data in line […]
GENEVA, Oct. 25, 2022 /PRNewswire/ — Following our communication last week “MedAlliance to be acquired by Cordis”, MedAlliance is pleased to make the following announcement: SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial. This is the first sustained limus release coronary […]
ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placebo Primary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 months DbCM is a form of heart failure affecting […]
